Published in Radiother Oncol on June 01, 2009
TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol (2011) 1.46
Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment. BMC Cancer (2010) 0.90
Lung cancer. Radiotherapy in lung cancer: Actual methods and future trends. Rep Pract Oncol Radiother (2014) 0.82
Clinical implications of cytosine deletion of exon 5 of P53 gene in non small cell lung cancer patients. South Asian J Cancer (2016) 0.77
Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol (2013) 2.52
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol (2006) 1.61
β₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest (2012) 1.56
Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. Strahlenther Onkol (2014) 1.54
[Prolongation of latency or overall treatment time by unplanned radiation pauses. The clinical importance of compensation]. Strahlenther Onkol (2005) 1.48
B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood (2012) 1.47
Development of a novel robot for transperineal needle based interventions: focal therapy, brachytherapy and prostate biopsies. J Urol (2012) 1.43
Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res (2006) 1.43
Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centers. Oncology (2011) 1.40
Residual inhibition functions overlap tinnitus spectra and the region of auditory threshold shift. J Assoc Res Otolaryngol (2008) 1.34
Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. Radiother Oncol (2006) 1.32
Hyperbaric oxygen therapy in the treatment of radio-induced lesions in normal tissues: a literature review. Radiother Oncol (2004) 1.27
EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res (2011) 1.24
Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol (2009) 1.23
Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol Cancer Res (2007) 1.21
Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol (2012) 1.14
Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol (2007) 1.13
Cancer stem cells at the crossroads of current cancer therapy failures--radiation oncology perspective. Semin Cancer Biol (2010) 1.12
Age-related changes in the frequency of mesenchymal stem cells in the bone marrow of rats. Stem Cells Dev (2007) 1.11
PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J Clin Invest (2010) 1.09
Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol (2005) 1.09
Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur J Nucl Med Mol Imaging (2011) 1.09
Keynote comment: Radiotherapy in the age of molecular oncology. Lancet Oncol (2006) 1.08
Cancer stem cells and radiotherapy. Int J Radiat Biol (2009) 1.06
Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by gammaH2AX staining. Int J Radiat Biol (2009) 1.03
Mapping of transrectal ultrasonographic prostate biopsies: quality control and learning curve assessment by image processing. J Ultrasound Med (2009) 1.03
Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning? Radiother Oncol (2008) 1.01
Discovery of the cancer stem cell related determinants of radioresistance. Radiother Oncol (2013) 1.01
Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiother Oncol (2011) 1.01
Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol (2007) 1.00
Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. Radiother Oncol (2007) 0.99
Cancer stem cells: targets and potential biomarkers for radiotherapy. Clin Cancer Res (2011) 0.99
Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol (2005) 0.97
EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells. Cancer Res (2012) 0.96
Cancer stem cells as a predictive factor in radiotherapy. Semin Radiat Oncol (2012) 0.95
Influence of connective tissue diseases on the expression of radiation side effects: a systematic review. Radiother Oncol (2006) 0.95
Towards genetic prediction of radiation responses: ESTRO's GENEPI project. Radiother Oncol (2003) 0.95
Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. J Histochem Cytochem (2002) 0.95
Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma. Radiother Oncol (2012) 0.94
Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. Int J Radiat Oncol Biol Phys (2011) 0.94
Clinical perspectives of cancer stem cell research in radiation oncology. Radiother Oncol (2013) 0.93
Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol (2006) 0.93
A strategy for multimodal deformable image registration to integrate PET/MR into radiotherapy treatment planning. Acta Oncol (2013) 0.93
PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro. DNA Repair (Amst) (2008) 0.92
Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts. Int J Radiat Biol (2009) 0.92
Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res (2005) 0.92
CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116. Radiother Oncol (2009) 0.92
Quality of training in radiation oncology in Germany. Results of a 2006 survey. Strahlenther Onkol (2008) 0.92
Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother Oncol (2006) 0.91
Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours. Radiother Oncol (2011) 0.91
GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial. Radiother Oncol (2013) 0.91
Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. Radiother Oncol (2010) 0.90
Measuring tinnitus loudness using constrained psychophysical scaling. Am J Audiol (2009) 0.90
Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. Radiother Oncol (2013) 0.90
Fractionation in prostate cancer--is it time after all? Radiother Oncol (2010) 0.89
A number of bone marrow mesenchymal stem cells but neither phenotype nor differentiation capacities changes with age of rats. Mol Cells (2007) 0.89
Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res (2014) 0.89
Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys (2005) 0.89
Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer Metastasis Rev (2008) 0.89
Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin. Radiother Oncol (2006) 0.88
Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey. Radiother Oncol (2014) 0.88
Cullen's sign associated with metastatic esophageal carcinoma. J Hosp Med (2008) 0.88
Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res (2003) 0.88
New anticancer agents: in vitro and in vivo evaluation. In Vivo (2005) 0.88
Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiother Oncol (2004) 0.88
Aid to percutaneous renal access by virtual projection of the ultrasound puncture tract onto fluoroscopic images. J Endourol (2007) 0.88
BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts. Radiat Oncol (2014) 0.87
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC Cancer (2013) 0.87
American College of Chest Physicians consensus statement on the respiratory health effects of asbestos. Results of a Delphi study. Chest (2009) 0.87
Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas. Radiother Oncol (2009) 0.87
Guideline funding and conflicts of interest: article 4 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc (2012) 0.86
Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors. Int J Radiat Biol (2009) 0.86
EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: differential response of cancer stem cells and nontumourigenic cells? Radiother Oncol (2007) 0.86
Time in radiation oncology - keep it short! Radiother Oncol (2013) 0.86
Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis (2013) 0.86
Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. Int J Radiat Oncol Biol Phys (2005) 0.86
First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPI-II. Radiother Oncol (2010) 0.85
Individualization of cancer treatment from radiotherapy perspective. Mol Oncol (2012) 0.85
Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. Radiother Oncol (2011) 0.84